Compare · MDLN vs PSTV
MDLN vs PSTV
Side-by-side comparison of Medline Inc. (MDLN) and PLUS THERAPEUTICS Inc. (PSTV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and PSTV operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $48.08B, about 1804.9x PSTV ($26.6M).
- PSTV has been more active in the news (8 items in the past 4 weeks vs 7 for MDLN).
- MDLN has more recent analyst coverage (25 ratings vs 3 for PSTV).
- Company
- Medline Inc.
- PLUS THERAPEUTICS Inc.
- Price
- -
- -
- Market cap
- $48.08B
- $26.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 7
- 8
- Recent ratings
- 25
- 3
PLUS THERAPEUTICS Inc.
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium NanoLiposomes, a patented radiotherapy for patients with recurrent glioblastoma, which is in the Phase 1 dose-finding clinical trial. The company is also developing DocePLUS, a patented chemotherapy for patients with solid tumors that is in Phase 1 clinical trial; and DoxoPLUS, a generic chemotherapy for patients with ovarian cancer. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Latest MDLN
- SEC Form 8-K filed by Medline Inc.
- Medline to build Midwestern network with new 800,000-square-foot facility in Van Buren Township, Mich.
- SEC Form 4 filed by Medline Inc.
- Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care
- SEC Form 4 filed by Medline Inc.
- MEDLINE INC. MDLN INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 12.8% Share Drop
- Medline to report third quarter 2026 results on November 4, 2026
- INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Medline Inc. to Contact Law Firm
- Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
- SEC Form 4 filed by Chief Executive Officer Boyle James M
Latest PSTV
- PLUS THERAPEUTICS Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Chief Financial Officer Sims Andrew John Hugh Macintyre converted options into 2,985 shares, increasing direct ownership by 30% to 12,926 units (SEC Form 4)
- Director Guse Kyle converted options into 921 shares, increasing direct ownership by 100% to 1,843 units (SEC Form 4)
- Chief Executive Officer Hedrick Marc H converted options into 16,439 shares, increasing direct ownership by 37% to 60,922 units (SEC Form 4)
- Director Van Es-Johansson An converted options into 921 shares, increasing direct ownership by 100% to 1,843 units (SEC Form 4)
- Director Andrews Ronald Asbury converted options into 921 shares, increasing direct ownership by 100% to 1,843 units (SEC Form 4)
- Director Hawkins Richard J converted options into 921 shares, increasing direct ownership by 60% to 2,450 units (SEC Form 4)
- Director Clowes Howard converted options into 921 shares, increasing direct ownership by 46% to 2,902 units (SEC Form 4)
- SEC Form D filed by PLUS THERAPEUTICS Inc.
- PLUS THERAPEUTICS Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities